Pharsight

1. List of Juxtapid drug patents

Application	Filing Date	Opposition Party	Legal Status
EP05724887A	2013-08-21	Stein, Evan MD PhD	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7932268	August, 2015	FWD Entered	The Trustees of the University of Pennsylvania)	Coalition for Affordable Drugs VIII
US8618135	August, 2015	FWD Entered	The Trustees of the University of Pennsylvania	COALITION FOR AFFORDABLE DRUGS VIII, LLC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433617	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US9861622	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US10016404	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US10555938	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US8618135	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US9265758	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US9364470	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US7932268	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Aug, 2027 (4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 30MG BASE	CAPSULE;ORAL	Prescription
EQ 40MG BASE	CAPSULE;ORAL	Discontinued
EQ 60MG BASE	CAPSULE;ORAL	Discontinued

JUXTAPID family patents

United States

Japan

Slovenia

Korea, Republic of

Canada

Portugal

Croatia

New Zealand

Poland

Australia

Denmark

Netherlands

Lithuania

Spain

Cyprus

European Union

2. List of Mycapssa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265812	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US8535695	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US9566246	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US8329198	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US11510963	AMRYT	Method of treating diseases	Feb, 2036 (12 years from now)
US10695397	AMRYT	Method of treating diseases	Feb, 2036 (12 years from now)
US11052126	AMRYT	Method of treating diseases	Feb, 2036 (12 years from now)
US10238709	AMRYT	Method of treating diseases	Feb, 2036 (12 years from now)
US11338011	AMRYT	Method of treating diseases	Feb, 2036 (12 years from now)
US11141457	AMRYT	Oral octreotide therapy and contraceptive methods	Dec, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL